www.ultragenyx.com Open in urlscan Pro
2606:4700::6812:1bc7  Public Scan

Form analysis
0 forms found in the DOM

Text Content

 * Patient Advocacy

 * U.S.
   * ARGENTINA
   * BRAZIL
   * CANADA (English)
   * CANADA (Français)
   * CHILE
   * COLOMBIA
   * Germany
   * ITALY
   * JAPAN
   * MEXICO
   * PERU
   * UNITED KINGDOM
   * UNITED STATES

 * Home
 * Ultra-Committed
   
   * * * To transform the lives of as many people living with rare diseases as
         possible, we dedicate ourselves every day to the development and
         delivery of treatments of rare diseases where none currently exist.
     
     
     * * ULTRA-COMMITTED
         
         Learn more
     * * Leadership
       * Access to Our Therapies
       * Early Access
       * Policy Government and Public Affairs
         Access Resources
         
       * Corporate Responsibility
       * Grants & Contributions
       * Patient Advocacy
   * * 
 * Research
   
   * * * We develop therapies for rare and ultrarare genetic diseases by
         exploring an array of drug modalities to select the best treatment
         strategy for each genetic disease we are studying.
     
     
     * * RESEARCH
         
         Learn more
     * * Our Science
       * Our Gene Therapy Platform
       * Our Pipeline
         DTX401 for GSDIaDTX301 for OTC DeficiencyUX701 for Wilson DiseaseUX143
         for OIGTX-102 for ASUX111 for MPS IIIAUX055 for CDD
         
       * Our Clinical Trial Transparency Commitment
 * Medicines
 * Partnerships
 * Join Our Team
   
   * * * We have built a talented team and a vibrant, people-first culture. We
         share a passion for helping those living with rare diseases.
     
     
     * * JOIN OUR TEAM
         
         Learn More
     * * Culture
       * Benefits
       * Current Opportunities
       * Internships, Co-ops & Postdoctoral Programs
       * Contact Us
 * Newsroom
   
   * * * Access news releases, presentations, and blog posts to follow the
         latest developments at Ultragenyx.
     
     
     * * NEWSROOM
         
         Learn More
     * * Press Releases
       * Blog
       * Media Asset Library
 * Investors

 * Patient Advocacy

 * U.S.
   * ARGENTINA
   * BRAZIL
   * CANADA (English)
   * CANADA (Français)
   * CHILE
   * COLOMBIA
   * Germany
   * ITALY
   * JAPAN
   * MEXICO
   * PERU
   * UNITED KINGDOM
   * UNITED STATES

Menu Close



FOR AVERY AND ADDISON, WE GO BEYOND EVERY DAY


ADVANCING MEDICINES FOR RARE DISEASES

Learn more
 * Facebook
 * Linkdin
 * Twitter

#GoingBeyondEveryDay

Avery and Addison are living with osteogenesis imperfecta.


LEADING WITH PURPOSE. EVERY DAY.

“Ultragenyx was founded to advance innovative medicines for rare and ultrarare
diseases that have never been treated before. We are delivering transformative
therapies across multiple indications, and we have one of the most robust and
diverse clinical pipelines in rare disease. Our focus is on doing the right
things for patients both during development and commercialization to deliver on
the promise of these therapies in a way that's meaningful for rare disease
communities.”

Emil D. Kakkis, M.D., Ph.D.
Chief Executive Officer and President


LEADERSHIP

Our team of passionate biopharmaceutical leaders combines deep expertise in drug
development and commercialization

Meet our leadership team


PIPELINE

We have one of the largest and most diverse pipelines in rare disease

Explore our pipeline


CAREERS

Join our talented team

Browse current opportunities


LATEST NEWS

View more news >
July 17, 2024

Ultragenyx Announces Successful End-of-Phase 2 Meeting with FDA for GTX-102
Angelman Syndrome Program

Read press release
June 20, 2024

Ultragenyx Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

Read press release
June 13, 2024

Ultragenyx Announces Pricing of Public Offering of Common Stock and Pre-Funded
Warrants

Read press release


RARE PERSPECTIVE

Insights and information on our approach to collaborating with rare disease
communities, supporting our teammates at Ultragenyx, and developing new
therapies for rare disease

Read our blog >
© 2023 Ultragenyx Pharmaceutical Inc. All rights reserved.
 * PATIENT ADVOCACY
 * CONTACT US
 * PRIVACY POLICY
 * COOKIE POLICY
 * SITE MAP

 * Facebook
 * Linkedin
 * Twitter

This site uses cookies to provide you with a more responsive and personalized
service. By clicking “Accept” below, you agree to the use of cookies on this
site. Please read our Cookie Policy and Privacy Policy for more information on
the use of cookies on this website.

Accept Do not accept